Chemoradiation followed by chemotherapy before resection for borderline pancreatic adenocarcinoma

American Journal of Surgery

Volumn 195, Issue 3, 2008, Pages 318-321

  Brown, Kimberly M ^a   Siripurapu, Veeriah ^a   Davidson, Marson ^a   Cohen, Steven J ^a   Konski, Andre ^a   Watson, James C ^a   Li, Tiaynu ^a   Ciocca, Vince ^a   Cooper, Harry ^a   Hoffman, John P ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

Borderline resectable; Cancer; Chemoradiation; Chemotherapy; Neoadjuvant; Pancreas; Pancreatic cancer

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; ERLOTINIB; FLUOROURACIL; GEMCITABINE; OXALIPLATIN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; MALE; MORBIDITY; MORTALITY; MULTIPLE CYCLE TREATMENT; PANCREAS ADENOCARCINOMA; PANCREATICODUODENECTOMY; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT RESPONSE; UNIVARIATE ANALYSIS; ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; CANCER STAGING; MIDDLE AGED; PANCREAS TUMOR; PATHOLOGY; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PANCREATICODUODENECTOMY; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 40749098149     PISSN: 00029610     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjsurg.2007.12.017     Document Type: Article

References (16)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2007. CA Cancer J Clin 57 (2007) 43-66
2. Kalser M.H., and Ellenberg S.S. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 120 (1985) 899-903
3. Yeo C.J., Abrams R.A., Grochow L.B., et al. Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg 225 (1997) 621-633
4. Spitz F.R., Abbruzzese J.L., Lee J.E., et al. Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol 15 (1997) 928-937
5. Pendurthi T.K., Hoffman J.P., Ross E., et al. Preoperative versus postoperative chemoradiation for patients with resected pancreatic adenocarcinoma. Am Surg 64 (1998) 686-692
6. Millikan K.W., Deziel D.J., Silverstein J.C., et al. Prognostic factors associated with resectable adenocarcinoma of the head of the pancreas. Am Surg 65 (1999) 618-623
7. Pingpank J.F., Hoffman J.P., Ross E.A., et al. Effect of preoperative chemoradiotherapy on surgical margin status of resected adenocarcinoma of the head of the pancreas. J Gastrointest Surg 5 (2001) 121-130
8. Neoptolemos J.P., Stocken D.D., Dunn J.A., et al. Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg 234 (2001) 758-768
9. Sasson A.R., Wetherington R.W., Hoffman J.P., et al. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: analysis of histopathology and outcome. Int J Gastrointest Cancer 34 (2003) 121-128
10. Varadhachary G.R., Tamm E.P., Abbruzzese J.L., et al. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol 13 (2006) 1035-1046
11. Ammori J.B., Colletti L.M., Zalupski M.M., et al. Surgical resection following radiation therapy with concurrent gemcitabine in patients with previously unresectable adenocarcinoma of the pancreas. J Gastrointest Surg 7 (2003) 766-772
12. Schlieman M.G., Ho H.S., and Bold R.J. Utility of tumor markers in determining resectability of pancreatic cancer. Arch Surg 138 (2003) 951-955 discussion 955-6
13. Ko A.H., Hwang J., Venook A.P., et al. Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer. Br J Cancer 93 (2005) 195-199
14. Berger A.C., Meszoely I.M., Ross E.A., et al. Undetectable preoperative levels of serum CA 19-9 correlate with improved survival for patients with resectable pancreatic adenocarcinoma. Ann Surg Oncol 11 (2004) 644-649
15. Talamonti M.S., Small Jr. W., Mulcahy M.F., et al. A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma. Ann Surg Oncol 13 (2006) 150-158
16. Huguet F., Andre T., Hammel P., et al. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol 25 (2007) 326-331